Asthma Severity in Women: The Influence of Training and Menopause (ATOM)

June 17, 2021 updated by: Vibeke Backer, Rigshospitalet, Denmark

The ATOM Study: Asthma Severity in Women: The Influence of Training and Menopause

Introduction: Late-onset asthma in women is characterized by poor disease control and reduced quality of life despite intensive treatment with inhaled steroid and beta2-agonist. The condition is further worsened at menopause due to the loss of estrogen leading to increased asthma exacerbation frequency, increased airway inflammation and decreased lung function. Exercise training may increase disease control of asthma patients, but to what extent the same effect is seen in postmenopausal women with late-onset asthma is unknown. These asthma patients represent a phenotype that is characterized by low eosinophilic airway inflammation, severe symptoms, moderate obesity and poor response to conventional medicine. Thus, our hypothesis is that regular physical exercise is especially associated with an improvement in asthma control in this phenotype. The aim of this project is to test this hypothesis and to assess whether an improvement is associated with reduced local and systemic inflammation, change in heart function, lung function and/or body composition.

Study design: 40 postmenopausal women with late-onset asthma are recruited via the outpatient clinic at the Respiratory Department at Bispebjerg Hospital and through advertisement. The participants are randomized 1:1 into two groups. One group performs supervised exercise training (spinning) three times per week for 12 weeks while the other group is a control group. Before and after the intervention asthma control, local and systemic inflammation, heart function and body composition is measured.

Results: Analysis will be performed to detect changes within and between the groups before and after intervention. Primary outcome is change in ACQ (Asthma Control Questionnaire). Local and systemic inflammation is measured by changes in bronchial challenge to methacholine, sputum cell count and blood tests. Furthermore, secondary outcomes include change in heart function measured by stress-echocardiography and change in body composition measured by Dual-energy X-ray absorptiometry (DEXA).

Conclusion: There are to date no prospective studies that can support recommendations containing asthma rehabilitation with supervised regular physical activity for postmenopausal women. Thus, this study will provide novel understanding of the importance of physical activity in a chronic disease such as asthma.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Overall study design

The study is a single-blinded randomized controlled intervention study. Forty postmenopausal women with late-onset asthma (>16 years at debut) are recruited from the asthma outpatient-clinic at Bispebjerg Hospital or other hospital/practitioner in the region and/or by advertisement. The participants are block-randomized into two groups of 20, where one group is control and the other undergoes a period of regular exercise training. The investigators will be blinded and will not know whether the subjects have trained or not.

Detailed study design

Participants allocated to the exercise training group undergo a training intervention consisting of 45 minutes of intermittent high intensity aerobic spinning training three times per week for 12 weeks. Participants allocated to the control group will continue usual care without training. No changes to current treatment will be made by the investigators on any of the groups.

The training will consist of short periods of high intensity intervals where subjects reach above 80% of maximal oxygen consumption. Spinning sessions will be fully supervised by trained instructors with a bachelor of sports and science or bachelor of medicine and conducted in the Department of Nutrition, Exercise and Sports, University of Copenhagen. Subjects will wear heart rate monitors to ensure adherence to the training protocol. Within two weeks, before and after the intervention, participants from both groups undergo 3 days of testing.

To ensure equal compliance with asthma medication both groups will receive daily electronic reminders. Once a week, all participants will be asked about their compliance to their medication.

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Copenhagen, Denmark, 2400
        • Respiratory research unit, Bispebjerg University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Late onset asthma (Debut ≥ 16 years of age)
  • ACQ ≥ 1.25
  • Daily treatment for asthma (GINA 2 and above)
  • Age 45 - 75
  • Postmenopausal defined as no menstruation for 6 months, Serum Follicle stimulating hormone >20 International Units per Liter and P-Estradiol nmol/L <0.09
  • BMI 25 - 35
  • Positive bronchial challenge to methacholine, mannitol or positive reversibility to beta2-agonist now or historically
  • Untrained (no participation in vigorous exercise for more than 1 hour per week during the last 2 months)
  • Capable of exercising on a bike

Exclusion Criteria:

  • Unable to speak and understand Danish or English.
  • Current or former smokers (>6 months cessation) with >20 years of daily smoking with 20 cigarettes per day.
  • Other respiratory disease of clinical significance
  • Cardiovascular: Unstable ischemic heart disease, myocardial infarction within the last 12 months, symptomatic heart failure (EF <40%), symptomatic heart arrhythmia (documented with ECG), uncontrolled hypertension (>155/100)
  • Any disorder that is not stable and in the opinion of the investigator could affect the safety of the subject throughout the study
  • Subjects, who by investigators determination, will not be able to adhere to study protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Aerobic exercise intervention
Aerobic exercise by high intensity interval training, 3 times per week for 12 weeks
High Intensity Interval Training (HIIT)
No Intervention: Control group
No intervention for 12 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Asthma control - Asthma Control Questionnaire (ACQ)
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention
Changes in Asthma Control Questionnaire (ACQ) 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use)
-21 to 0 days before intervention and 0 to 14 days post intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Heart Rate Variability
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in:

- Heart rate variability

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart rhytm
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in:

- Heart rhythm

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart Rate
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in:

- electrocardiography

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Strain
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Strain

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Ejection fraction
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Ejection fraction

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Tricuspid annular plane systolic excursion
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Tricuspid annular plane systolic excursion

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Right ventricular function
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Right ventricular function

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Pulmonary pressure
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Pulmonary pressure

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Lung covered cor
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Lung covered cor

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Blood pressure
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention
Blood pressure
-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Cardiac output
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention
Cardiac output
-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Stroke volume
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention
Stroke volume
-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Total peripheral resistance
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention
Total peripheral resistance
-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Leukocytes + differential cell count count
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Leukocytes + differential cell count count

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Interleukin 6
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Interleukin 6

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Interleukin 8
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Interleukin 8

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Other interleukins

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Tumor Necrosis Factor alpha
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Tumor Necrosis Factor alpha

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Total immunoglobulin E, Specific immunoglobulin E
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

  • Total immunoglobulin E
  • Specific immunoglobulin E
-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - high sensitivity c reactive protein
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- high sensitivity c reactive protein

-21 to 0 days before intervention and 0 to 14 days post intervention
Local airway inflammation - Sputum cell count
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Sputum cell count

-21 to 0 days before intervention and 0 to 14 days post intervention
Local airway inflammation - Fraction of exhaled nitric oxide
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Fraction of exhaled nitric oxide

-21 to 0 days before intervention and 0 to 14 days post intervention
Local airway inflammation - Hyperreactivity to inhaled methacholine
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Hyperreactivity to inhaled methacholine

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Total body fat

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Lean body mass

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Muscle mass

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Weight

-21 to 0 days before intervention and 0 to 14 days post intervention
Microbiome
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention
Changes in the microbiota in sputum, oral cavity and nasal cavity before and after the training intervention
-21 to 0 days before intervention and 0 to 14 days post intervention
Compliance - Foster score
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Change in

- Foster score Answers describe last weeks medicine use. Answers range form 0/7 - 7/7 with low values being worse.

-21 to 0 days before intervention and 0 to 14 days post intervention
Other asthma related questionnaires - Nijmegen questionnaire
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Nijmegen questionnaire Values range from 0-64 and values below 20 are considered normal.

-21 to 0 days before intervention and 0 to 14 days post intervention
Other asthma related questionnaires - Mini Asthma Quality of Life Questionnaire (miniAQLQ)
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Mini Asthma Quality of Life Questionnaire (miniAQLQ) 7-point Likert scale (7 = not impaired at all - 1 = severely impaired).

-21 to 0 days before intervention and 0 to 14 days post intervention
Other asthma related questionnaires - Hospital Anxiety and Depression Scale (HADS) 2 items with 7 questions regarding anxiety and depression. (0 = no sign of depression/anxiety, 21 = maximal signs of anxiety/depression)
Time Frame: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Hospital Anxiety and Depression Scale (HADS)

-21 to 0 days before intervention and 0 to 14 days post intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Vibeke Backer, Physician, Respiratory Research Unit, Bispebjerg Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 12, 2019

Primary Completion (Actual)

May 1, 2021

Study Completion (Actual)

May 1, 2021

Study Registration Dates

First Submitted

November 9, 2018

First Submitted That Met QC Criteria

November 19, 2018

First Posted (Actual)

November 20, 2018

Study Record Updates

Last Update Posted (Actual)

June 23, 2021

Last Update Submitted That Met QC Criteria

June 17, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data that support the results of this study will be made available immediately, with no end date, after deidentification and upon reasonable request.

IPD Sharing Time Frame

Immediately after publication with no end date.

IPD Sharing Access Criteria

Data will be made available upon reasonable request to achieve the aims of the reasonable request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Late-Onset Asthma

Clinical Trials on Aerobic exercise

Subscribe